Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma

Cancer Cell

Volumn 31, Issue 6, 2017, Pages 833-843.e5

  Lionakis, Michail S ^a   Dunleavy, Kieron ^b   Roschewski, Mark ^b   Widemann, Brigitte C ^b   Butman, John A ^c   Schmitz, Roland ^b   Yang, Yandan ^b   Cole, Diane E ^b   Melani, Christopher ^b   Higham, Christine S ^b   Desai, Jigar V ^b   Ceribelli, Michele ^d   Chen, Lu ^d   Thomas, Craig J ^b,d   Little, Richard F ^b   Gea Banacloche, Juan ^b   Bhaumik, Sucharita ^b   Stetler Stevenson, Maryalice ^b   Pittaluga, Stefania ^b   Jaffe, Elaine S ^b   Heiss, John ^b   Lucas, Nicole ^b   Steinberg, Seth M ^b   Staudt, Louis M ^b   Wilson, Wyndham H ^b   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

ABC DLBCL; Aspergillus fumigatus; B cell receptor signaling; BTK; ibrutinib; macrophage; primary CNS lymphoma

Indexed keywords

AMINOPTERIN; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; CD79B ANTIGEN; CYTARABINE; DOXORUBICIN; DRUG METABOLITE; ENOXAPARIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; IBRUTINIB; METHOTREXATE; MITOMYCIN; MYELOID DIFFERENTIATION FACTOR 88; PCI 45227; PRALATREXATE; PYRIMETHAMINE; STEROID; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; CD79 ANTIGEN; ENZYME INHIBITOR; LYMPHOCYTE ANTIGEN RECEPTOR; MYD88 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID-TO-PLASMA RATIO; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIFFUSE LARGE B CELL LYMPHOMA; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENTIATION; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; FOLLOW UP; FUNGUS IMMUNITY; GENE MUTATION; HAND FOOT SYNDROME; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; IC50; LUNG ASPERGILLOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMOCYSTIS JIROVECI; POSITRON EMISSION TOMOGRAPHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; ASPERGILLOSIS; BRAIN NEOPLASMS; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENE INACTIVATION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOMA; METABOLISM; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD79; ASPERGILLOSIS; BRAIN NEOPLASMS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; GENE KNOCKOUT TECHNIQUES; HUMANS; LYMPHOMA; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 85019938452     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.04.012     Document Type: Article

References (57)

1. Abrey, L.E., Batchelor, T.T., Ferreri, A.J., Gospodarowicz, M., Pulczynski, E.J., Zucca, E., Smith, J.R., Korfel, A., Soussain, C., DeAngelis, L.M., et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J. Clin. Oncol. 23 (2005), 5034–5043.
2. Ambady, P., Holdhoff, M., Bonekamp, D., Wong, F., Grossman, S.A., Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy. CNS Oncol. 4 (2015), 393–398.
3. Anders, C.K., Adamo, B., Karginova, O., Deal, A.M., Rawal, S., Darr, D., Schorzman, A., Santos, C., Bash, R., Kafri, T., et al. Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS One, 8, 2013, e61359.
4. Baldwin, A.S., Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 107 (2001), 241–246.
5. Bliss, C.I., The toxicity of poisons applied jointly. Ann. Appl. Biol. 26 (1939), 585–615.
6. Braggio, E., Van Wier, S., Ojha, J., McPhail, E., Asmann, Y.W., Egan, J., da Silva, J.A., Schiff, D., Lopes, M.B., et al. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin. Cancer Res. 21 (2015), 3986–3994.
7. Bruno, A., Boisselier, B., Labreche, K., Marie, Y., Polivka, M., Jouvet, A., Adam, C., Figarella-Branger, D., Miquel, C., Eimer, S., et al. Mutational analysis of primary central nervous system lymphoma. Oncotarget 5 (2014), 5065–5075.
8. Byrne, J.C., Ni Gabhann, J., Stacey, K.B., Coffey, B.M., McCarthy, E., Thomas, W., Jefferies, C.A., Bruton's tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin. J. Immunol. 190 (2013), 5207–5215.
9. Caraglia, M., Addeo, R., Costanzo, R., Montella, L., Faiola, V., Marra, M., Abbruzzese, A., Palmieri, G., Budillon, A., Grillone, F., et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother. Pharmacol. 57 (2006), 34–39.
10. Chapuy, B., Roemer, M.G., Stewart, C., Tan, Y., Abo, R.P., Zhang, L., Dunford, A.J., Meredith, D.M., Thorner, A.R., Jordanova, E.S., et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127 (2016), 869–881.
11. Chignard, M., Balloy, V., Sallenave, J.M., Si-Tahar, M., Role of Toll-like receptors in lung innate defense against invasive aspergillosis. Distinct impact in immunocompetent and immunocompromised hosts. Clin. Immunol. 124 (2007), 238–243.
12. Dagenais, T.R., Keller, N.P., Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin. Microbiol. Rev. 22 (2009), 447–465.
13. Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463 (2010), 88–92.
14. de Vries, R., Huang, M., Bode, N., Jejurkar, P., Jong, J., Sukbuntherng, J., Sips, L., Weng, N., Timmerman, P., Verhaeghe, T., Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution. Bioanalysis 7 (2015), 2713–2724.
15. Dubourdeau, M., Athman, R., Balloy, V., Huerre, M., Chignard, M., Philpott, D.J., Latge, J.P., Ibrahim-Granet, O., Aspergillus fumigatus induces innate immune responses in alveolar macrophages through the MAPK pathway independently of TLR2 and TLR4. J. Immunol. 177 (2006), 3994–4001.
16. Dubovsky, J.A., Beckwith, K.A., Natarajan, G., Woyach, J.A., Jaglowski, S., Zhong, Y., Hessler, J.D., Liu, T.M., Chang, B.Y., Larkin, K.M., et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122 (2013), 2539–2549.
17. Ferreri, A.J., Blay, J.Y., Reni, M., Pasini, F., Spina, M., Ambrosetti, A., Calderoni, A., Rossi, A., Vavassori, V., Conconi, A., et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J. Clin. Oncol. 21 (2003), 266–272.
18. Fiedler, K., Sindrilaru, A., Terszowski, G., Kokai, E., Feyerabend, T.B., Bullinger, L., Rodewald, H.R., Brunner, C., Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. Blood 117 (2011), 1329–1339.
19. Fishman, J.A., Infection in solid-organ transplant recipients. N. Engl. J. Med. 357 (2007), 2601–2614.
20. Mathews Griner, L.A., Guha, R., Shinn, P., Young, R.M., Keller, J.M., Liu, D., Goldlust, I.S., Yasgar, A., McKnight, C., et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl. Acad. Sci. USA 111 (2014), 2349–2354.
21. Hattori, K., Sakata-Yanagimoto, M., Okoshi, Y., Goshima, Y., Yanagimoto, S., Nakamoto-Matsubara, R., Sato, T., Noguchi, M., Takano, S., Ishikawa, E., et al. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma. Br. J. Haematol. 177 (2016), 492–494.
22. Herbst, S., Shah, A., Mazon Moya, M., Marzola, V., Jensen, B., Reed, A., Birrell, M.A., Saijo, S., Mostowy, S., Shaunak, S., Armstrong-James, D., Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus. EMBO Mol. Med. 7 (2015), 240–258.
23. Horwood, N.J., Page, T.H., McDaid, J.P., Palmer, C.D., Campbell, J., Mahon, T., Brennan, F.M., Webster, D., Foxwell, B.M., Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J. Immunol. 176 (2006), 3635–3641.
24. Khan, W.N., Alt, F.W., Gerstein, R.M., Malynn, B.A., Larsson, I., Rathbun, G., Davidson, L., Muller, S., Kantor, A.B., Herzenberg, L.A., et al. Defective B cell development and function in Btk-deficient mice. Immunity 3 (1995), 283–299.
25. Kasperkovitz, P.V., Cardenas, M.L., Vyas, J.M., TLR9 is actively recruited to Aspergillus fumigatus phagosomes and requires the N-terminal proteolytic cleavage domain for proper intracellular trafficking. J. Immunol. 185 (2010), 7614–7622.
26. Koukourakis, M.I., Koukouraki, S., Fezoulidis, I., Kelekis, N., Kyrias, G., Archimandritis, S., Karkavitsas, N., High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br. J. Cancer 83 (2000), 1281–1286.
27. Kraan, W., Horlings, H.M., van Keimpema, M., Schilder-Tol, E.J., Oud, M.E., Scheepstra, C., Kluin, P.M., Kersten, M.J., Spaargaren, M., Pals, S.T., High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J., 3, 2013, e139.
28. Kraan, W., van Keimpema, M., Horlings, H.M., Schilder-Tol, E.J., Oud, M.E., Noorduyn, L.A., Kluin, P.M., Kersten, M.J., Spaargaren, M., Pals, S.T., High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 28 (2014), 719–720.
29. Langner-Lemercier, S., Houillier, C., Soussain, C., Ghesquieres, H., Chinot, O., Taillandier, L., Soubeyran, P., Lamy, T., Morschhauser, F., Benouaich-Amiel, A., et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 18 (2016), 1297–1303.
30. Lewis, R.E., Cahyame-Zuniga, L., Leventakos, K., Chamilos, G., Ben-Ami, R., Tamboli, P., Tarrand, J., Bodey, G.P., Luna, M., Kontoyiannis, D.P., Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 56 (2013), 638–645.
31. Limper, A.H., Hoyte, J.S., Standing, J.E., The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J. Clin. Invest. 99 (1997), 2110–2117.
32. Lin, N.U., Bellon, J.R., Winer, E.P., CNS metastases in breast cancer. J. Clin. Oncol. 22 (2004), 3608–3617.
33. Lionakis, M.S., Kontoyiannis, D.P., Glucocorticoids and invasive fungal infections. Lancet 362 (2003), 1828–1838.
34. Liu, X., Smith, B.J., Chen, C., Callegari, E., Becker, S.L., Chen, X., Cianfrogna, J., Doran, A.C., Doran, S.D., Gibbs, J.P., et al. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab. Dispos. 34 (2006), 1443–1447.
35. Nakamura, T., Tateishi, K., Niwa, T., Matsushita, Y., Tamura, K., Kinoshita, M., Tanaka, K., Fukushima, S., Takami, H., Arita, H., et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol. Appl. Neurobiol. 42 (2016), 279–290.
36. Ngo, V.N., Young, R.M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470 (2011), 115–119.
37. Ni Gabhann, J., Hams, E., Smith, S., Wynne, C., Byrne, J.C., Brennan, K., Spence, S., Kissenpfennig, A., Johnston, J.A., Fallon, P.G., Jefferies, C.A., Btk regulates macrophage polarization in response to lipopolysaccharide. PLoS One, 9, 2014, e85834.
38. Palmer, C.D., Mutch, B.E., Workman, S., McDaid, J.P., Horwood, N.J., Foxwell, B.M., Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFkappaB activity. Blood 111 (2008), 1781–1788.
39. Pham-Ledard, A., Cappellen, D., Martinez, F., Vergier, B., Beylot-Barry, M., Merlio, J.P., MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J. Invest. Dermatol. 132 (2012), 2118–2120.
40. Plebani, A., Soresina, A., Rondelli, R., Amato, G.M., Azzari, C., Cardinale, F., Cazzola, G., Consolini, R., De Mattia, D., Dell'Erba, G., et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin. Immunol. 104 (2002), 221–230.
41. Ramaprakash, H., Ito, T., Standiford, T.J., Kunkel, S.L., Hogaboam, C.M., Toll-like receptor 9 modulates immune responses to Aspergillus fumigatus conidia in immunodeficient and allergic mice. Infect. Immun. 77 (2009), 108–119.
42. Ramirez-Ortiz, Z.G., Specht, C.A., Wang, J.P., Lee, C.K., Bartholomeu, D.C., Gazzinelli, R.T., Levitz, S.M., Toll-like receptor 9-dependent immune activation by unmethylated CpG motifs in Aspergillus fumigatus DNA. Infect. Immun. 76 (2008), 2123–2129.
43. Rao, G.V., Tinkle, S., Weissman, D.N., Antonini, J.M., Kashon, M.L., Salmen, R., Battelli, L.A., Willard, P.A., Hoover, M.D., Hubbs, A.F., Efficacy of a technique for exposing the mouse lung to particles aspirated from the pharynx. J. Toxicol. Environ. Health A 66 (2003), 1441–1452.
44. Rubenstein, J.L., Gupta, N.K., Mannis, G.N., Lamarre, A.K., Treseler, P., How I treat CNS lymphomas. Blood 122 (2013), 2318–2330.
45. Rubenstein, J.L., Hsi, E.D., Johnson, J.L., Jung, S.H., Nakashima, M.O., Grant, B., Cheson, B.D., Kaplan, L.D., Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J. Clin. Oncol. 31 (2013), 3061–3068.
46. Ruchlemer, R., Ben Ami, R., Lachish, T., Ibrutinib for chronic lymphocytic leukemia. N. Engl. J. Med. 374 (2016), 1593–1594.
47. Scheers, E., Leclercq, L., de Jong, J., Bode, N., Bockx, M., Laenen, A., Cuyckens, F., Skee, D., Murphy, J., Sukbuntherng, J., Mannens, G., Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab. Dispos. 43 (2015), 289–297.
48. Siegal, T., Horowitz, A., Gabizon, A., Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 83 (1995), 1029–1037.
49. Singh, N., Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Curr. Opin. Infect. Dis. 18 (2005), 342–345.
50. Stadler, N., Hasibeder, A., Aranda Lopez, P., Teschner, D., Desuki, A., Kriege, O., Weber, A.N., Schulz, C., Michel, C., Hess, G., Radsak, M.P., The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1 mediated neutrophil activation. Haematologica, 2017, 10.3324/haematol.2016.152017.
51. Taniguchi, K., Takata, K., Chuang, S.S., Miyata-Takata, T., Sato, Y., Satou, A., Hashimoto, Y., Tamura, M., Nagakita, K., Ohnishi, N., et al. Frequent MYD88 L265P and CD79B mutations in primary breast diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 40 (2016), 324–334.
52. Vail, D.M., Amantea, M.A., Colbern, G.T., Martin, F.J., Hilger, R.A., Working, P.K., Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin. Oncol. 31 (2004), 16–35.
53. Vater, I., Montesinos-Rongen, M., Schlesner, M., Haake, A., Purschke, F., Sprute, R., Mettenmeyer, N., Nazzal, I., Nagel, I., Gutwein, J., et al. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia 29 (2015), 677–685.
54. Leopold Wager, C.M., Wormley, F.L. Jr., Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections. Mucosal Immunol. 7 (2014), 1023–1035.
55. Wilson, W.H., Treatment strategies for aggressive lymphomas: what works?. Hematology Am. Soc. Hematol. Educ. Program 2013 (2013), 584–590.
56. Wilson, W.H., Young, R.M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.J., Williams, P.M., Shaffer, A.L., Gerecitano, J., et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med. 21 (2015), 922–926.
57. Young, R.M., Wu, T., Schmitz, R., Dawood, M., Xiao, W., Phelan, J.D., Xu, W., Menard, L., Meffre, E., Chan, W.C., et al. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proc. Natl. Acad. Sci. USA 112 (2015), 13447–13454.